ENTRY       D10578            Mixture   Drug
NAME        Ledipasvir and sofosbuvir;
            Harvoni (TN)
PRODUCT     HARVONI (Gilead Sciences)
  GENERIC   LEDIPASVIR AND SOFOSBUVIR (Asegua Therapeutics LLC)
COMPONENT   Ledipasvir [DR:D10442], Sofosbuvir [DR:D10366]
CLASS       Antiviral
             DG03198  Anti-HCV agent
            Transporter substrate
             DG01665  ABCB1 substrate
             DG01913  ABCG2 substrate
REMARK      Therapeutic category: 6250
            ATC code: J05AP51
            Product: D10578<JP/US>
EFFICACY    Antiviral
  DISEASE   Chronic hepatitis C virus infection [DS:H00413]
TARGET      HCV NS5A [KO:K22275]
            HCV NS5B [KO:K22472]
  PATHWAY   ko03230(K22275+K22472)  Viral genome structure
            ko03240(K22275+K22472)  Viral replication
            ko05160(K22275+K22472)  Hepatitis C
METABOLISM  Transporter: ABCB1 [HSA:5243], ABCG2 [HSA:9429]
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             J ANTIINFECTIVES FOR SYSTEMIC USE
              J05 ANTIVIRALS FOR SYSTEMIC USE
               J05A DIRECT ACTING ANTIVIRALS
                J05AP Antivirals for treatment of HCV infections
                 J05AP51 Sofosbuvir and ledipasvir
                  D10578  Ledipasvir and sofosbuvir &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Antivirals
              Anti-hepatitis C (HCV) Agents
               Ledipasvir/ Sofosbuvir
                D10578  Ledipasvir and sofosbuvir
            Therapeutic category of drugs in Japan [BR:br08301]
             6  Agents against pathologic organisms and parasites
              62  Chemotherapeutics
               625  Antivirals
                6250  Antivirals
                 D10578  Ledipasvir and sofosbuvir
            Drug groups [BR:br08330]
             Antiviral
              DG03198  Anti-HCV agent
               D10578  Ledipasvir and sofosbuvir
             Transporter substrate
              DG01665  ABCB1 substrate
               D10578  Ledipasvir and sofosbuvir
              DG01913  ABCG2 substrate
               D10578  Ledipasvir and sofosbuvir
            Drug classes [BR:br08332]
             Antiviral
              DG03198  Anti-HCV agent
               D10578  Ledipasvir and sofosbuvir
            Antimicrobials [BR:br08307]
             Antivirals
              Genome replication inhibitor
               HCV NS5A/NS5B inhibitor
                D10578  Ledipasvir and sofosbuvir &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D10578
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D10578
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D10578
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D10578
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug transporters
              D10578
DBLINKS     PubChem: 254741540
            ChEBI: 85082
///
